Abstract
Background: Lung cancer is the most frequent cause of cancer-related death. In the last decades, the introduction of targeted therapies and more recently, of immunotherapy, has led to significant improvements in different outcomes of this malignant neoplasm.
Objective: The present review provides a balanced overview of most recent targeted therapies and immunotherapies patented for the treatment of lung cancer.
Methods: An extensive scientific literature and patent databases search were performed to identify peerreviewed studies containing information on recently patented drugs for the treatment of lung cancer, with a particular focus on their safety data and recently patented combinations.
Results: The development of therapies directed to different pathways involved in the tumor angiogenesis, proliferation, and metastasis has transformed the clinical practice of lung malignancies. Several clinical trials have shown an improvement in terms of progression-free survival and overall survival in patients with advanced/metastatic lung cancer. Safety data, extracted from clinical trials and from the WHO global database of adverse drug reactions (VigiAccessTM database), show that recently patented drugs for the treatment of lung cancer are well-tolerated and most of the adverse events reported are mild to moderate.
Conclusion: Currently, a consistent number of new drugs and combinations have been introduced for the treatment of patients with advanced-stage lung cancer. Safety data remain essential to better assess the long-term risk/benefit ratio of these valuable emerging therapies. The new patents’ development could provide further significant improvements for lung cancer treatment.
Keywords: Immunotherapy, lung cancer, patent, side effects, targeted therapy, toxicity.
[2]
Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer 2001; 31(2-3): 139-48.
[3]
National Center for Chronic Disease Prevention and Health Promotion
(US) Office on Smoking and Health. The Health Consequences
of Smoking-50 Years of Progress: A Report of the Surgeon
General Atlanta (GA): Centers for Disease Control and Prevention
(US) Available at:. http://www.ncbi.nlm.nih.gov/books/NBK179276/2014 (Accessed on: August 22, 2018).
[4]
Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest 2001; 120(5): 1577-83.
[5]
Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer 2014; 120(18): 2883-92.
[6]
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92-8.
[7]
Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl. 5): v1-v27.
[8]
Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012; 7(5): 866-72.
[9]
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311(19): 1998-2006.
[10]
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.
[11]
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2(2)127137
[http://dx.doi.org/10.1038/35052073]
[http://dx.doi.org/10.1038/35052073]
[12]
Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 1996; 32(12): 2070-4.
[13]
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26(15): 2442-9.
[14]
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-24.
[15]
Swaisland HC1, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder Smith CH, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005; 44(11): 1165-77.
[16]
Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80(2): 136-45.
[17]
Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, et al. Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer 2011; 74(1): 98-102.
[18]
Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19(8): 2240-7.
[19]
Marshall J, Hwang J, Eskens FA, et al. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs 2013; 31(2): 399-408.
[http://dx.doi.org/10.1007/s10637-012-9890-y]
[http://dx.doi.org/10.1007/s10637-012-9890-y]
[20]
Wind S, Schmid M, Erhardt J, Goeldner R-G, Stopfer P. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 2013; 52(12): 1101-9.
[http://dx.doi.org/10.1007/s40262-013-0091-4]
[http://dx.doi.org/10.1007/s40262-013-0091-4]
[21]
Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, et al. Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer. Br J Clin Pharmacol 2017; 83(6): 1216-26.
[22]
Lee Y, Lee GK, Y.L. Lee, Zhang W. De novo EGFR T790M mutation
in lung cancer patients harboring sensitive EGFR mutations. American Association for Cancer Research- Annual Meeting San
Diego, CA (2014).
[23]
Liao B-C, Lin C-C, Lee J-H, Chih-Hsin Yang J. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci 2016; 23: 86.
[24]
Hirota T, Muraki S, Ieiri I. Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet 2019; 58(4): 403-20.
[25]
Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: First-generation or next-generation TKI? Nat Rev Clin Oncol 2018; 15(11): 694-708.
[26]
Shi JG, Bowman KJ, Chen X, Maleski J, Leopold L, Yeleswaram S. Population pharmacokinetic and pharmacodynamic modeling of epacadostat in patients with advanced solid malignancies. J Clin Pharmacol 2016; 57(6): 720-9.
[http://dx.doi.org/10.1002/jcph.855]
[http://dx.doi.org/10.1002/jcph.855]
[27]
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18: 874-86.
[28]
Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, et al. Three-year follow-up of an alectinib Phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol 2017; 35(14): 1515-21.
[29]
Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016; 374(1): 5461.
[http://dx.doi.org/10.1056/NEJMoa1508887]
[http://dx.doi.org/10.1056/NEJMoa1508887]
[30]
Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man Phase 1 trial. Lancet Oncol 2017; 18: 1590-9.
[31]
Stopfer P, Roth W, Mross K, Judson IR, Kienast J, Kaiser R, et al. Pharmacokinetic characterization of BIBF 1120, an orally active
triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced
cancer patients. EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer. EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics - 18th Meeting Prague, Czech Republic (2006(.
[32]
Stopfer P, Rathgen K, Bischoff D, Lüdtke S, Marzin K, Kaiser R, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011; 41(4): 297-311.
[33]
Marzin K, Kretschmar G, Luedtke D, Kraemer S, Kuelzer R, Schlenker‐Herceg R, et al. Pharmacokinetics of nintedanib in subjects with hepatic impairment. J Clin Pharmacol 2018; 58(3): 357-63.
[http://dx.doi.org/10.1002/jcph.1025]
[http://dx.doi.org/10.1002/jcph.1025]
[34]
European Medicines Agency - Find medicine - Ofev. Available at:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124 (Accessed on: August 03, 2018.)
[35]
Von Pawel J, Kaiser R, Eschbach C, et al. A double blind Phase II study of BIBF 1,120 in patients suffering from relapsed advanced Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2007; 25(Suppl. 18): 7635.
[http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7635]
[http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7635]
[36]
Nintedanib extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy.. https://www.europeanpharmaceuticalreview.com/news/21704/nintedanib-extended-survival-beyond-one-year-advanced-adenocarcinoma-patients-prior-first-line-chemotherapy/ (Accessed on: March 19, 2018.)
[37]
Primary Progression-Free Survival Endpoint Met in Phase III Study of Nintedanib Plus Docetaxel in Second-Line Advanced NSCLC. Available at:. http://ereprints.elsevier.es/9PB6033/abstract (Accessed on: March 19, 2018.)
[38]
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC. Available at:. https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-presents-progression-free-survival-data-investigational-afatinib (Accessed on: March 19, 2018)
[39]
Efficacy and Safety of Lorlatinib in ALK+ Non-Small Cell Lung
Cancer (NSCLC) Patients (pts) with >1 Prior ALK Tyrosine
Kinase Inhibitor (TKI): A Phase 1/2 Study. Available at:. https://meetinglibrary.asco.org/record/153628/abstract (Accessed
on: March 19, 2018)
[40]
Pfizer Presents Full Results from Phase 2 Study of Next- Generation Investigational ALK-Inhibitor Lorlatinib in ALKPositive and ROS1-Positive Advanced Non-Small Cell Lung Cancer. Available at:. http://press.pfizer.com/press-release/pfizer-presents-full-results-phase-2-study-next-generation-investigational-alk-inhibit (Accessed on: March 19, 2018)
[41]
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer. Available at:. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_promising_data_from_next_generation_alk_ros1_inhibitor_in_advanced_non_small_cell_lung_cancer (Accessed on: March 19, 2018)
[42]
Mitsudomi T, Ahn M-J, Bazhenova L, Blackhall F, Hida T, Tarruella MM, et al. Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies. ESMO- 2017 2017; Abstr. 1348P. Available at:. http://www.esmo.org/Conferences/ESMO-2017-Congress
[43]
Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy
of AZD9291 in Patients With Locally Advanced/Metastatic
NSCLC Whose Disease Has Progressed With Previous EGFR TKI
and Whose Tumours Are EGFR and T790M Mutation Positive. Available at:. https://ichgcp.net/clinical-trials-registry/NCT02094261 (Accessed on: May, 2019)
[44]
Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014; 6: 423-32.
[45]
Pantano S, Li F, Li N, Boral A. Combination of Ceritinib with an EGFR Inhibitor. US20170252335 . (2017).
[46]
Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 2014; 57(16): 7031-41.
[47]
Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100: 35-83.
[48]
Yan DHSE, DeRyckere DA, Graham DK, Wan J. Methods for the treatment of cancer. US20170266188 . (2017).
[49]
Zhang M, Guoliang L, Wang Y, Wang Y, Zhao S, Haihong P, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: A meta-analysis. Nature 2017; 7(1): 10255.
[http://dx.doi.org/10.1038/ s41598-017-10925-7]
[http://dx.doi.org/10.1038/ s41598-017-10925-7]
[50]
Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34(26): 3119-25.
[51]
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, Phase 2 trial. Lancet 2016; 387(10031): 1909-20.
[52]
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, Phase 2 randomised controlled trial. Lancet 2016; 387(10030): 1837-46.
[53]
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627-39.
[54]
European Medicines Agency - Find medicine - Opdivo. Available at:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124. (Accessed on: August 22, 2019)
[55]
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, bms-936558, ono-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33(18): 2004-12.
[56]
Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6(1): 58-66.
[57]
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387(10027): 1540-50.
[58]
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375(19): 1823-33.
[59]
Rihawi K, Gelsomino F, Sperandi F, Melotti B, Fiorentino M, Casolari L, et al. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence. Ther Adv Respir Dis 2017; 11(9): 353-73.
[60]
Ahamadi M, Freshwater T, Prohn N, Li CH, de Alwis DP, de Greef R, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: A Humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6(1): 49-57.
[61]
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A Phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389(10066): 255-65.
[62]
Socinski M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-301.
[http://dx.doi.org/10.1056/NEJMoa1716948]
[http://dx.doi.org/10.1056/NEJMoa1716948]
[63]
European Medicines Agency - Find medicine – Tecentriq. Available at:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medi-cines/human/medicines/004143/human_med_002166.jsp&mid=WC0b01ac058001d124 (Accessed on: August 05, 2018)
[64]
Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017; 7: 5532.
[65]
Powles T, O’Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a Phase 1/2 open-label study. JAMA Oncol 2017; 3(9) e172411
[66]
Food and Drug Administration (FDA). Approved Drugs - Durvalumab (Imfinzi). Available at:. https://www.fda.gov/drugs/ informationondrugs/approveddrugs/ucm555930.htm (Accessed on: August 08, 2018)
[67]
Bristol-Myers Squibb. Two-Year Overall Survival Data from Two
Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit
In Patients with Advanced Non-Small Cell Lung Cancer. Available at:. https://news.bms.com/press-release/bmy/two-year-overall-survival-data-two-pivotal-opdivo-nivolumab-trials-demonstrate-sus
[68]
Bristol-Myers Squibb. Opdivo (nivolumab) Demonstrates Superior
Survival Compared to Standard of Care (docetaxel) for Previously-
Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial. Available at:. https://news.bms.com/press-release/opdivo-nivolumab-demonstrates-superior-survival-compared-standard-care-docetaxel-previ
[69]
Bristol-Myers Squibb. Bristol-Myers Squibb Receives Positive
CHMP Opinion in the European Union for Nivolumab (Opdivo,
Nivolumab BMS) for the Treatment of Advanced Squamous Non-
Small Cell Lung Cancer in Previously-Treated Patients. Available at:. https://news.bms.com/press-release/bristol-myers-squibb-receives-positive-chmp-opinion-european-union-nivolumab-opdivo-ni
[70]
Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, et al. FDA Approval Summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-Line therapy and beyond. Oncologist 2017; 22(11): 1392-9.
[71]
Barlesi F, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 2016; 27(Suppl. 6).
[http://dx.doi.org/10.1093/annonc/mdw435.43]
[http://dx.doi.org/10.1093/annonc/mdw435.43]
[72]
Mitrofan L, Sahni M, Dhingra D, Mistry H, Anger C. Treatment paradigm shift in NSCLC: Patient data analysis from 2005 to 2016. Ann Oncol 2017; 28(Suppl. 5): v460-96.
[73]
AstraZeneca AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress Available at:. https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-surv-ival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advan-ced-unresectable-lung-cancer-at-esmo-2017-congress-08092017. html
[74]
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377(20): 1919-29.
[75]
AstraZeneca US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer Available at:. https://www.astrazeneca. com/media-centre/press-releases/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-180202018.html
[77]
Balmanoukian AS, Antonia SJ, Hwu W, Hamid O, Gutierrez M, Jamal R. Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC. J of Clin Oncol 2017; 35(Suppl. 15): 9085.
[78]
Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol 2018; 10.
[79]
Coric V, Keler T, Davis T. Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment. US20170174774 . (2017).
[80]
Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005; 115(2): 170-8.
[81]
Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, Höller C, et al. PD-1 Blockade promotes emerging checkpoint inhibitors in enhancing t cell responses to allogeneic dendritic cells. Front Immunol 2017; 8: 572.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
38
7